Icatibant API is a pharmaceutical-grade synthetic peptide and selective bradykinin B2 receptor antagonist indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults. By blocking the action of bradykinin, it rapidly reduces swelling, pain, and inflammation associated with HAE attacks.
Icatibant is formulated as a subcutaneous injectable solution and is widely used in emergency management of hereditary angioedema episodes. It offers rapid symptom relief and has become an important therapy for patients with bradykinin-mediated angioedema.
Manufactured under WHO-GMP-certified facilities, our Icatibant API provides high purity, excellent stability, and consistent batch quality. Each batch is supplied with comprehensive regulatory documentation, including Certificate of Analysis (CoA), Material Safety Data Sheet (MSDS), and Technical Data Sheet (TDS).
Icatibant API is used in injectable pharmaceutical formulations for the treatment of acute attacks of hereditary angioedema (HAE).
Icatibant selectively blocks bradykinin B2 receptors, preventing bradykinin from causing swelling, pain, and inflammation during hereditary angioedema attacks.
Yes. We provide CoA, MSDS, Technical Data Sheet (TDS), Product Specifications, and complete regulatory documentation.
Yes. We supply Icatibant API in commercial quantities with worldwide export support.
Get Bulk Quote via WhatsApp